Dr Reddy Generics Company Intelligence Report
Company Intelligence Report
| Product Code | ESP00686 |
| Publication Date | March 2009 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 20 |
| ISBN Number | not applicable |
Dr Reddy Generics Company Intelligence Report
Company Intelligence Report
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Contents
- Executive Summary
- Introduction
- Dr Reddy's launches US Specialty Business
- Dr Reddy's realigns Global Generics geography portfolio
- Products
- Dr Reddy's files fondaparinux ANDA for Alchemia
- Dr Reddy's ANDA Approvals, 2002-09
- Recent product approvals
- Divalproex
- Dr Reddy's announces ANDA approvals
- Lamotrigine
- Sumatriptan (US authorised generic)
- Dr Reddy's enters Indian inhalers market
- Venlafaxine
- Atorvastatin+ramipril
- Financial results
- Latest Quarterly Results, Q309
- Global Generics
- Dr Reddy's: Third Quarter Results, in Rs millions
- Dr Reddy's: Third Quarter Results, in US$ millions
- Dr Reddy's crosses US$150 million revenue milestone in Russia and CIS
- Latest fiscal year results, FY2008
- Dr Reddy's: Full Year Results, Fiscal year to 31st March in Rs millions
- Dr Reddy's: Full Year Results, Fiscal year to 31st March in US$ millions
- Segment Data
- Branded Formulations
- Active Pharmaceutical Ingredients and Intermediates
- Dr Reddy's: Revenues from Key API Products Across all Regions, in Rs millions
- Dr Reddy's: Revenues from Key API Products Across all Regions, in US$ millions
- Generics
- Custom Pharmaceutical Services (CPS)
- Dr Reddy's: Full Year Results by Segments, Fiscal year to 31st March in Rs millions
- Dr Reddy's: Full Year Results by Segments, Fiscal year to 31st March in US$ millions
- DR REDDY'S LABORATORIES GENERIC COMPANIES ANALYSIS
- Major developments
- Dr Reddy's, Stada and Teva report successes in AOK tenders in the German market
- Mergers, acquisitions & agreements
- Dr Reddy's makes dermatology product advances
- TMH/Dr Reddy's sign agreement to create self-injectable product
- Dr Reddy's and Albemarle sign ibuprofen API deal
- Aquapharm signs new agreement and extends R&D licence with Dr Reddy's
- Dr Reddy's to buy BASF contract manufacturing operations
- Dowpharma's UK Small Molecules business sold to Dr Reddy's
- Dr Reddy's acquires Jet Generici
- TM/Dr Reddy's enter drug-discovery collaboration
- Dr Reddy's/SkyePharma collaborate on feasibility study
- Litigation
- Dr Reddy's gains favourable omeprazole ruling
- Dr Reddy's enter desloratadine litigation settlement
- Teva and Dr Reddy's settle carvedilol suit
- AstraZeneca sues Dr Reddy's over generic zafirlukast
- US court affirms that Eisai's Aciphex patent is valid and enforceable
- Dr Reddy's and Novartis settle rivastigmine litigation
- Forest and Merz file additional lawsuit for Namenda patent infringement
- Contact Details